Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRADE: Abemaciclib Dose Escalation in Early-Stage HR+/HER2- Breast Cancer
NCT06001762Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Composite Endpoint: Number of Participants With Abemaciclib Discontinuation for Any Reason, Abemaciclib Dose Reductions, or the Inability of Study Participants to Reach the Target Dose of Abemaciclib at 12 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06001762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001762.